Education
About Us
Working with TipRanks
Follow Us
Quest Diagnostics (DGX)
NYSE:DGX
DGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$135.47 - $179.99
Previous CloseN/A
Volume143.08K
Average Volume (3M)1.01M
Market Cap
$19.76B
Enterprise Value$22.45B
Total Cash (Recent Filing)$188.00M
Total Debt (Recent Filing)$6.57B
Price to Earnings (P/E)22.4
Beta0.26
Next Earnings
Jul 23, 2025EPS Estimate
2.57Next Dividend Ex-Date
Jul 07, 2025Dividend Yield1.81%
Share Statistics
EPS (TTM)2.21
Shares Outstanding111,635,475
10 Day Avg. Volume766,387
30 Day Avg. Volume1,012,092
Financial Highlights & Ratios
PEG Ratio0.93
Price to Book (P/B)2.54
Price to Sales (P/S)0.00
P/FCF Ratio16.97
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue0.58
Enterprise Value/Gross Profit6.79
Enterprise Value/Ebitda3.04
Forecast
1Y Price Target
$189.31Price Target Upside5.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Quest Diagnostics News
See All DGX News
Bulls Say, Bears Say
Bulls Say
Growth ProspectsManagement expressed greater conviction in Quest Diagnostics' long-term growth prospects, emphasizing a strong fundamental backdrop and positive trends in healthcare and diagnostics.
Market PositionDGX has gained share in Physician Lab Services and in Hospital Lab Services, which it expects to continue, outgrowing the market in both segments.
Revenue And EPS GrowthThe company expects significant revenue and EPS growth in 2025, driven by improved utilization and diagnostic innovation.
Tariff ManagementManagement is not concerned with tariff impacts, noting they are manageable and included in current guidance.
Bears Say
Potential Reimbursement CutsThe company now sees a cut to CMS reimbursement in '26 (up to 15%) as a 50% probability, which would drive a $100M headwind but enable industry consolidation and share gains.
Regulatory Compliance CostsDGX is still expecting to incur up to the prior $10M investment needed to improve regulatory compliance.
Ownership Overview
0.43% Insiders
29.39% Mutual Funds
14.98% Other Institutional Investors
27.49% Public Companies and Individual Investors
DGX FAQ
What was Quest Diagnostics’s price range in the past 12 months?
Quest Diagnostics lowest stock price was $135.47 and its highest was $179.99 in the past 12 months.
What is Quest Diagnostics’s market cap?
Quest Diagnostics’s market cap is $19.76B.
When is Quest Diagnostics’s upcoming earnings report date?
Quest Diagnostics’s upcoming earnings report date is Jul 23, 2025 which is in 39 days.
How were Quest Diagnostics’s earnings last quarter?
Quest Diagnostics released its earnings results on Apr 22, 2025. The company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.152 by $0.058.
Is Quest Diagnostics overvalued?
According to Wall Street analysts Quest Diagnostics’s price is currently Undervalued.
Does Quest Diagnostics pay dividends?
Quest Diagnostics pays a Quarterly dividend of $0.8 which represents an annual dividend yield of 1.81%. See more information on Quest Diagnostics dividends here
What is Quest Diagnostics’s EPS estimate?
Quest Diagnostics’s EPS estimate is 2.57.
How many shares outstanding does Quest Diagnostics have?
Quest Diagnostics has 111,635,475 shares outstanding.
What happened to Quest Diagnostics’s price movement after its last earnings report?
Quest Diagnostics reported an EPS of $2.21 in its last earnings report, beating expectations of $2.152. Following the earnings report the stock price went up 6.784%.
Which hedge fund is a major shareholder of Quest Diagnostics?
Currently, no hedge funds are holding shares in DGX
Quest Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$189.31 (5.05% Upside)
$189.31 (5.05% Upside)
Blogger Sentiment
Bullish
DGX Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 330.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $145.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.57%
12-Months-Change
Fundamentals
Return on Equity
13.35%
Trailing 12-Months
Asset Growth
13.21%
Trailing 12-Months
Company Description
Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
DGX Company Deck
DGX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong revenue growth, successful partnerships, and strategic initiatives driving the business forward. However, there were some challenges, including impacts from weather, labor costs, and a strike affecting LifeLabs. Overall, the positive aspects outweighed the negatives, as evidenced by reaffirmed guidance and successful new product launches.Read More>DGX Revenue Breakdown
97.39% Diagnostic Information Services
2.61% All other operating segments
DGX Stock 12 Month Forecast
Average Price Target
$189.31
▲(5.05%Upside)